Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Zhaao et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2020.110825
Zhaao et al., Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2020.110825
Sep 2020   Source   PDF  
  All Studies   Meta
Small study with 14 combined favipiravir/tocilizumab, 7 favipiravir, and 5 tocilizumab patients suggesting that tocilizumab combined with or without favipiravir can improve pulmonary inflammation and inhibit progression.
Zhaao et al., 30 Sep 2020, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Biomedicine & Pharmacotherapy 133 (2021) 110825 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size Hong Zhao a, b, 1, Qi Zhu c, 1, Chi Zhang a, 1, Jiawen Li a, Ming Wei d, Yuhong Qin e, Guilin Chen c, Ke Wang d, Junhua Yu f, Zhao Wu a, Xianxiang Chen g, *, Guiqiang Wang a, b, ** a Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China Peking University International Hospital, Beijing, China Department of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, 430030, China d Wuhan Jinyintan Hospital, No. 1 Yintan Road, Dongxihu District, Wuhan, 430040, China e Emergency Department of Peking University International Hospital, Life-Science Park, Changping District, Beijing, 102206, China f Ezhou Central Hospital, 9 Wenxing Road, Ezhou City, Hubei Province, 463000, China g Surgical Department, Wuhan Pulmonary Hospital, No. 28 Baofeng Road, Wuhan, 430030, China b c A R T I C L E I N F O A B S T R A C T Keywords: Tocilizumab Favipiravir Interleukin-6 COVID-19 SARS-CoV-2 Background: Since December 2019, COVID-19 has spread to almost every corner of the world. In theory, toci­ lizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6. We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID-19. Methods: This was a multicenter trial in adults with COVID-19. Patients were randomly assigned (3:1:1) to a 14day combination of favipiravir combined with tocilizumab (combination group), favipiravir, and tocilizumab. The primary outcome was the cumulative lung lesion remission rate (lung CT examination indicated absorption of lung inflammation). Results: Between Feb 2 and March 15, 2020, 26 patients were recruited; 14 were randomly assigned to the combination group, 7 were assigned to the favipiravir group and 5 were assigned to the tocilizumab group. The cumulative lung lesion remission rate at day 14 was significantly higher in combination group as compared with favipiravir group (P = 0.019, HR 2.66 95 % CI [1.08–6.53]). And there was also a significant difference between tocilizumab and favipivavir (P = 0.034, HR 3.16, 95 % CI 0.62–16.10). In addition, there was no significant difference between the combination group and the tocilizumab group (P = 0.575, HR 1.28 95 %CI 0.39–4.23). Furthermore, combined therapy can also significantly relieve clinical symptoms and help blood routine to return to normal. No serious adverse events were reported. Conclusion: Tocilizumab combined with or without favipiravir can effectively improve the pulmonary inflam­ mation of COVID-19 patients and inhibit the deterioration of the disease.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop